Hormel Foods Corp vs Johnson & Johnson — how do they compare? Hormel Foods Corp trades at $19.19 (market cap $10.69B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 57.8× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Johnson & Johnson for 129 Days on average.
| HRL | JNJ | |
|---|---|---|
Market Cap | $10.69B | $618.09B |
Volume | 10,041,387 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $278.43 |
52-Week Low | $19.19 | $186.00 |
Typical Hold Time | 99 Days | 129 Days |
Enterprise Value | $12.67B | $646.37B |
Dividend Yield | 6.02% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though recent quarters beat EPS estimates. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, while maintaining a 60-year dividend streak. Cash flow trends show improvement from 2025's negative $71M to projected 2026 positive $245M.
HRL presents a value opportunity with 25% upside to consensus target of $24.25, supported by dividend stability. However, declining profit margins and elevated valuation multiples pose headwinds. The Brakebush integration execution and consumer spending trends will be critical for reversing earnings pressure amid competitive food markets.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →